[Clinical study of human pancreatic cancer-associated antigen (SPan-1 antigen) in hepatobiliary and pancreatic diseases].
We studied clinical significance of serum SPan-1 antigen, which is human pancreatic cancer associated antigen, in hepatobiliary and pancreatic diseases employing newly developed kit. The sensitivity of serum SPan-1 antigen levels for pancreatic cancer, gallbladder carcinoma, hepatocellular carcinoma, bile duct cancer were 90.9%, 77.8%, 60.7%, 60.0% respectively. No correlation was found between serum SPan-1 antigen levels and total bilirubin levels. SPan-1 positivity in patients with hepatic disease including hepatocellular carcinoma was rather high, but there were few cases more than 100 U/ml. The mechanism of the elevated level was supposed to be release of the antigen from bile-duct epithelium, and this must be taken into consideration at diagnosis referred to serum SPan-1 antigen level.
Nakata
B
B
First Department of Surgery, Osaka City University Medical School.
Chung
Y S
YS
Yokomatsu
H
H
Tanaka
H
H
Sawada
T
T
Nishiwaki
H
H
Satake
K
K
Umeyama
K
K
Seki
S
S
D000951:Antigens, Neoplasm / Q000032:analysis*; D001660:Biliary Tract Diseases / Q000276:immunology*; D006801:Humans; D008107:Liver Diseases / Q000276:immunology*; D010182:Pancreatic Diseases / Q000276:immunology*
D000951:Antigens, Neoplasm; C059729:pancreatic associated antigen, SPan-1